Takeda Oncology Development Pipeline

First Page		Document Content
Date: 2016-05-06 15:30:27 Seattle Genetics Monoclonal antibodies Brentuximab vedotin Oncology Protein kinase inhibitor Proteasome inhibitor Antineoplastic drugs Cancer Proteasome Tumors of the hematopoietic and lymphoid tissues Targeted therapy Phosphoinositide 3-kinase inhibitor		Takeda Oncology Development Pipeline Add to Reading List Source URL: www.takedaoncology.com Download Document from Source Website File Size: 211,15 KB Share Document on Facebook

	Takeda Oncology Development Pipeline DocID: 1obev - View Document
	SOUTHERN ARIZONA CLINICAL TRIALS Breast Cancer Veliparib ABT-888 Neoadj TNBC Brentuximab Vedotin in Older Pts with HL DocID: 1kuWg - View Document
	BREAKOUT SESSION I ABSTRACT PRESENTATION 14 Brentuximab Vedotin in Patients With CD30+ Mesothelioma Mesothelioma, Thymic Malignancies and Other Thoracic Malignancies DocID: 1cvRM - View Document
	Diamond Analytics Application Note: DA1018-A FLARE Wide Pore C18 Column: Separation of Antibody Drug Conjugate (ADC) Digested Sample Brentuximab-Vedotin was digested with endoproteinase Lys-C DocID: 19Rgd - View Document
	Draft Labeling Text - Redline, 2014Oct23 DocID: 18kAU - View Document